466 related articles for article (PubMed ID: 16968848)
1. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension.
Okin PM; Wachtell K; Devereux RB; Harris KE; Jern S; Kjeldsen SE; Julius S; Lindholm LH; Nieminen MS; Edelman JM; Hille DA; Dahlöf B
JAMA; 2006 Sep; 296(10):1242-8. PubMed ID: 16968848
[TBL] [Abstract][Full Text] [Related]
2. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Wedel H; Lindholm LH; Dahlöf B;
JAMA; 2004 Nov; 292(19):2343-9. PubMed ID: 15547161
[TBL] [Abstract][Full Text] [Related]
3. Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.
Okin PM
J Electrocardiol; 2009; 42(6):584-8. PubMed ID: 19631946
[TBL] [Abstract][Full Text] [Related]
4. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients.
Okin PM; Devereux RB; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Dahlöf B;
Ann Intern Med; 2007 Sep; 147(5):311-9. PubMed ID: 17785486
[TBL] [Abstract][Full Text] [Related]
5. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
Okin PM; Wachtell K; Kjeldsen SE; Julius S; Lindholm LH; Dahlöf B; Hille DA; Nieminen MS; Edelman JM; Devereux RB
Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):337-43. PubMed ID: 19808428
[TBL] [Abstract][Full Text] [Related]
6. Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients independent of blood pressure reduction - A LIFE review.
Bang CN; Devereux RB; Okin PM
J Electrocardiol; 2014; 47(5):630-5. PubMed ID: 25052475
[TBL] [Abstract][Full Text] [Related]
7. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Dahlof B;
Circulation; 2003 Aug; 108(6):684-90. PubMed ID: 12885747
[TBL] [Abstract][Full Text] [Related]
8. Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators.
Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Dahlöf B
Hypertension; 2000 Nov; 36(5):766-73. PubMed ID: 11082141
[TBL] [Abstract][Full Text] [Related]
9. Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study.
Larstorp AC; Okin PM; Devereux RB; Olsen MH; Ibsen H; Dahlöf B; Kjeldsen SE; Wachtell K
J Hum Hypertens; 2011 Mar; 25(3):178-85. PubMed ID: 20505749
[TBL] [Abstract][Full Text] [Related]
10. In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study.
Okin PM; Devereux RB; Harris KE; Jern S; Kjeldsen SE; Lindholm LH; Dahlöf B;
Hypertension; 2007 Nov; 50(5):984-90. PubMed ID: 17893425
[TBL] [Abstract][Full Text] [Related]
11. Combining ECG Criteria for Left Ventricular Hypertrophy Improves Risk Prediction in Patients With Hypertension.
Okin PM; Hille DA; Kjeldsen SE; Devereux RB
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29151037
[TBL] [Abstract][Full Text] [Related]
12. Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study.
Oikarinen L; Nieminen MS; Toivonen L; Viitasalo M; Wachtell K; Papademetriou V; Jern S; Dahlöf B; Devereux RB; Okin PM;
Am Heart J; 2003 May; 145(5):919-25. PubMed ID: 12766755
[TBL] [Abstract][Full Text] [Related]
13. Impact of alcohol habits and smoking on the risk of new-onset atrial fibrillation in hypertensive patients with ECG left ventricular hypertrophy: the LIFE study.
Ariansen I; Reims HM; Gjesdal K; Olsen MH; Ibsen H; Devereux RB; Okin PM; Kjeldsen SE; Dahlöf B; Wachtell K
Blood Press; 2012 Feb; 21(1):6-11. PubMed ID: 22070095
[TBL] [Abstract][Full Text] [Related]
14. Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients.
Okin PM; Hille DA; Kjeldsen SE; Lindholm LH; Edelman JM; Dahlöf B; Devereux RB
Am J Hypertens; 2010 Jul; 23(7):786-93. PubMed ID: 20395941
[TBL] [Abstract][Full Text] [Related]
15. Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study.
Larstorp AC; Ariansen I; Gjesdal K; Olsen MH; Ibsen H; Devereux RB; Okin PM; Dahlöf B; Kjeldsen SE; Wachtell K
Hypertension; 2012 Aug; 60(2):347-53. PubMed ID: 22753219
[TBL] [Abstract][Full Text] [Related]
16. In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
Wachtell K; Gerdts E; Aurigemma GP; Boman K; Dahlöf B; Nieminen MS; Olsen MH; Okin PM; Palmieri V; Rokkedal JE; Devereux RB
Blood Press; 2010 Jun; 19(3):169-75. PubMed ID: 20438307
[TBL] [Abstract][Full Text] [Related]
17. Racial differences in incident atrial fibrillation among hypertensive patients during antihypertensive therapy.
Okin PM; Bang CN; Wachtell K; Hille DA; Kjeldsen SE; Julius S; Dahlöf B; Devereux RB
Am J Hypertens; 2014 Jul; 27(7):966-72. PubMed ID: 24552888
[TBL] [Abstract][Full Text] [Related]
18. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
Okin PM; Devereux RB; Gerdts E; Snapinn SM; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Lindholm LH; Dahlöf B;
Circulation; 2006 Mar; 113(12):1588-96. PubMed ID: 16534012
[TBL] [Abstract][Full Text] [Related]
19. Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic hypertension; The LIFE study.
Larstorp AC; Okin PM; Devereux RB; Olsen MH; Ibsen H; Dahlöf B; Kjeldsen SE; Wachtell K
Am J Hypertens; 2012 Oct; 25(10):1101-9. PubMed ID: 22717544
[TBL] [Abstract][Full Text] [Related]
20. Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new heart failure.
Okin PM; Wachtell K; Gerdts E; Dahlöf B; Devereux RB
J Hypertens; 2014 Dec; 32(12):2472-8; discussion 2478. PubMed ID: 25340854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
